Pediatric follicular lymphoma (PFL) is a variant of follicular lymphoma (FL) presenting as localized lymphadenopathy in children. Unlike conventional adult FL, PFL typically does not recur or progress. Clear diagnostic criteria for PFL are lacking and it is uncertain whether this indolent lymphoma is defined by age or may occur in adults. We analyzed 27 FL in patients <40 years and found that all 21 cases that lacked a BCL2 gene abnormality (BCL2-N) (p<0.0001) and had >30% Ki67 proliferation index (HPI) (p=0.0007) were Stage I and did not progress or recur; in comparison, all 6 cases with BCL2 rearrangement and/or PI <30% were Stage III/IV and 5/6 recurred or progressed. In a separate cohort of 58 adult FL (≥18 years), all 13 BCL2-N/HPI cases were Stage I and none progressed or relapsed, whereas 11/15 Stage I cases with BCL2 gene abnormality and/or LPI relapsed or progressed (p=0.0001). The adult and pediatric BCL2-N/HPI FL cases had similar morphologic features. Our results confirm the highly indolent behavior of PFL and suggest that these are characterized by HPI and absence of BCL2 gene abnormality. PFL-like cases also occur in adults and are associated with indolent behavior in this patient population.
Introduction
Pediatric follicular lymphoma (PFL) is a variant of follicular lymphoma (FL) that occurs in children and typically presents as a clonal follicular lymphoid proliferation resulting in localized lymphadenopathy or extranodal lesions 1 . It has an excellent prognosis, with sustained complete remission achieved in most cases after systemic chemotherapy. Most reported cases of PFL lack the abnormal BCL2 protein expression or BCL2 gene rearrangements that characterize the majority of adult FL cases [2] [3] [4] . In addition, PFL is reported to have distinctive morphologic features, including large expansile follicles with numerous centroblasts. The WHO Classification includes PFL as a provisional subtype of follicular lymphoma, but does not provide a strict morphologic or immunophenotypic definition, nor does it provide criteria to distinguish it from conventional FL.
While the upper age limit defining 'pediatric' is generally considered to be 18 years, it is not known whether tumors with the biological features of PFL occur in adults. The distinction between conventional FL and PFL may be important, as conventional FL is generally considered an indolent but incurable disease, usually associated with recurrence after systemic chemotherapy. In contrast, recurrence after therapy in PFL is rare, despite its frequently high histologic grade, and some reports suggest that PFL may not recur after excision, even without systemic treatment 5, 6 .
In this study, we evaluated clonal nodal follicular B-cell proliferations occurring in patients less than 40 years of age, in order to identify morphologic, immunophenotypic, and molecular genetic parameters defining follicular proliferations in children and young adults that exhibit low potential for progression or recurrence. We then applied these parameters to a cohort of adult patients with FL to determine whether they could identify similar cases with low potential for progression or recurrence, irrespective of patient age.
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Materials and Methods

Patient Specimens
This study was approved by the institutional review board of Massachusetts General Hospital (MGH) . Clinical features of all cases, including staging, treatment, and outcome information, were obtained from patients' medical records. Cohort 1. Cohort 1 comprised 27 cases of nodal FL from patients less than 40 years of age. Cases were identified from the MGH pathology archives (including both cases biopsied at MGH and outside referral cases) between 1999 and 2010, via electronic search using the term "follicular,"
with original diagnoses of "follicular lymphoma" or "pediatric follicular lymphoma". All identified lymph node biopsies with FL diagnosed between 1999 and 2010 from patients <40 years old were included, with the exception of cases with concurrent diffuse large B-cell lymphoma (DLBCL) or those where diagnostic material could not be obtained. Cases lacking architectural effacement (e.g. follicular hyperplasia with clonal B cells), and cases of extranodal FL were also excluded. In all cases, B-cell clonality had been confirmed by flow cytometric analysis and/or polymerase chain reaction-based analysis of immunoglobulin heavy chain gene rearrangements using BIOMED-2 protocols and primer sets 7 . 
Morphological analysis
All routine hematoxylin and eosin (H&E)-stained sections, existing immunohistochemical stains, and pathology reports, flow cytometry reports, and any cytogenetic and/or molecular diagnostic reports, were reviewed by three of the authors (Cohort 1, AL, RPH, and NLH) or two of the authors (Cohort 2, AL and RPH) and the diagnosis of follicular lymphoma was confirmed for all cases. The following morphologic parameters were scored by consensus of two authors (AL and RPH) for both Cohort 1 and Cohort 2: Histologic grade according to WHO Classification criteria; average greatest diameter of neoplastic follicles based on measurement of 10 randomly selected follicles; presence of "starry-sky" appearance (numerous evenly dispersed phagocytic histiocytes) in >50% of follicles; and presence of marginal zone differentiation. In addition, the presence of diffuse areas was recorded for Cohort 2 cases. Histologic parameters were scored on the corresponding whole slide sections for all TMA cases.
Immunohistochemical Stains
Immunohistochemical stains were performed on formalin-fixed paraffin-embedded tissue sections (Cohort 1 & subset of Cohort 2) and TMA paraffin sections (subset of Cohort 2) using the Ventana Benchmark Autostainer (Ventana Medical Systems, Tucson, AZ) using the Ventana 3, 3' diaminobenzidine tetrahydrochloride kit according to the manufacturer's instructions. All cases were stained with primary antibodies for CD20, CD3, BCL6, BCL2, MUM1/IRF4 and Ki-67 (Ventana Benchmark). Cohort 1 cases were additionally stained with antibodies to CD10 and CD21. IHC for BCL2 was evaluated as the proportion of intrafollicular cells (scored as 0 for negative, and 1+, 2+, 3+ or 4+ for <26, 26-50, 51-75, >75% of intrafollicular cells, respectively).
In addition, the intensity of BCL2 staining was scored using a semiquantitative scale of staining intensity: intensity similar to T cells was scored as 3+, staining stronger than T-cells was scored as 4+, distinct staining weaker than T cells was scored as 2+, and faint staining was scored as 1+.
Estimation of proliferation index (PI) was based on percentage of Ki67 positive B cells within neoplastic follicles (on whole sections for all TMA cases). A cutoff of >30% PI to define highproliferation index (HPI) was based on prior outlier analysis of a large series of grade 1-2 FL cases 8 .
The scoring of BCL2 and Ki67 PI was performed by consensus of two of the authors (AL and RPH). IRF4 BAP. Detection of breakpoints affecting the IRF4 locus was performed on formalin-fixed paraffin-embedded sections using probes and protocols as previously described 9 .
Statistics
All statistical analysis was performed using Prism 4 software (Graph Pad 
Results
We initially reviewed cases of nodal FL in a pediatric and young adult patient population (Cohort 1) in order to identify pathologic features associated with indolent behavior in this population. We subsequently used these features to evaluate cases of adult nodal FL (Cohort 2) in order to determine if cases similar to "pediatric-type" FL occurred in adults and if these cases also exhibited indolent behavior.
Cohort 1: Follicular lymphomas in children, adolescents, and young adults, less than 40 years of age
Clinical Features
The 27 FL cases in Cohort 1 occurred in patients ranging from 8 to 36 years of age (median 18 years) (Table 1) 
Histologic features
The histologic features of the Cohort 1 FL cases are summarized in Table 1 . All cases were characterized by a follicular proliferation with partial (9/27, 33%) or subtotal to complete (18/27, 67%) effacement of the underlying lymph node architecture (Figure 1) . Clonal B cells comprised 20-96% (median 72%) of all the B cells in the 13 cases with available flow cytometry data.
Twenty-four of the cases had intact follicles whose size, shape and cellular composition were variable. In 3 cases, the follicles had poorly defined borders with prominent marginal zone differentiation at the follicle periphery, extending into interfollicular areas. The presence of BCL6+ and/or CD10+ expression within the interfollicular neoplastic component (3/3 cases) and/or the identification of CD10+ clonal B-cells by flow cytometry (2/3 cases) excluded the possibility of nodal marginal zone lymphoma in these cases. In the majority of the cases (15/27, 56%) the follicles were large and expansile (>2mm in average greatest diameter), including a subset of cases For personal use only. on April 20, 2017. by guest www.bloodjournal.org From (8/27, 30%) with markedly enlarged and/or coalescent follicles (>3 mm in average greatest diameter) ( Figure 1A ). The follicles were usually composed of a heterogenous admixture of variably-sized centrocytes, tingible body macrophages, follicular dendritic cells and centroblasts.
The centroblasts were often medium in size with vesicular chromatin and multiple nucleoli ( Figure   1B ). The centroblast count was >15 per high-power field in 10/27 cases (37%), consistent with grade 3A histology according to WHO classification criteria. In other cases, the large cells present within follicles mostly had centrocytic morphology, and centroblasts were not sufficiently increased to warrant a grade 3 designation ( Figure 1C ). There were no cases with a monomorphic proliferation of centroblasts (grade 3B histology). Among the 12 cases with an average follicle diameter of <2 mm, 9 showed a proliferation of relatively uniform, small follicles, of which 7 had a predominant population of small, irregular centrocytes resembling 'conventional' low-grade follicular lymphoma ( Figure 1D -E) .
BCL2 and MUM1/IRF4 immunohistochemistry and proliferation index
The immunohistochemical features of the Cohort 1 cases are summarized in Table 1 . There was strong, uniform BCL2 staining (3+ or 4+ intensity in >50% of neoplastic cells) in 5/27 cases (19%), with 9 additional cases having 2+ intensity BCL2 expression in 26-50% of the neoplastic cells ( Figure 2A , panels 5-6 and 2B, panels 5-6). Five of 25 cases (20%) evaluated showed MUM1/IRF4 staining in a subset (10-30%) of neoplastic cells (Supplemental Figure 1) . The Ki67 PI in the neoplastic follicles ranged from 5 to 95% (median 65%) ( Figure 2A , panels 1-2 and 2B, panels 1-2). Twenty-four of 27 cases (89%) had a PI of >30%, including 14/17 (82%) of the histologic grade 1-2 cases, which is within the spectrum of 'low-grade follicular lymphoma with high proliferation index'. 8 The 3 cases with <30% PI had PI values of 5%, 10%, and 10%; there were no cases with PI >10% and <40%. 
BCL2, BCL6, and MUM1/IRF4 FISH
Correlation of clinical and pathologic features with stage and outcome of Cohort 1 cases
Among clinical and histologic parameters assessed (Table 1) Patients with FL lacking any BCL2 gene abnormality and with >30% PI (BCL2-N/HPI), all of whom had Stage I disease, had superior progression-free survival compared to patients whose FL either had BCL2 rearrangement or PI <30% (p<0.0001, Figure 3A ). High PI alone (p=0.002) and absence of BCL2 gene abnormality alone (p=0.002) were also associated with superior progressionfree survival (data not shown). 
Clinicopathologic features of BCL2-N/HPI FL cases
The 21 BCL2-N/HPI FL cases occurred in patients between 8 and 36 years of age (median 17 years), with 43% of patients ≥ 18 years of age ( Figure 3B ). The majority of BCL2-N/HPI cases (14/21, 67%) were characterized by large, expansile follicles, frequently showing a "starry-sky" appearance ( Figure 1A-B, 1F) . In spite of the high PI, 12/21 (57%) BCL2-N/HPI cases were histologic grade 1-2, and 3 of these cases were morphologically indistinguishable from low-grade conventional FL, with numerous closely packed, similarly-sized small follicles composed of small to medium-sized centrocytes (Figure 4 ).
The patients with FL harboring a BCL2 gene rearrangement and/or a low PI were 17 to 34 years of age (median 23 years) ( Figure 3B ). The majority of cases (5/6) had small round follicles composed predominantly of small centrocytes, resembling conventional low-grade FL ( Figure 1D -E, 2B)
Cohort 2: Clinicopathologic analysis of follicular lymphoma cases in adults >=18 years
The 58 FL patients in Cohort 2 ranged from 18 to 85 years of age (median 57 years), with a median follow-up of 91 months. There were 28 Stage I patients, 0 Stage II patients, 11 Stage III patients, 15 Stage IV patients, and 4 patients of unknown stage. These FL cases were evaluated by BCL2 FISH and Ki67 staining and divided into 4 categories: FL lacking BCL2 gene abnormality and with PI >30% (BCL2-N/HPI); with BCL2 gene rearrangement or gain and PI >30% (BCL2-R/HPI); lacking BCL2 gene abnormality and with Ki67 <30% (BCL2-N/LPI); and with BCL2 gene rearrangement or gain and PI <30% (BCL2-R/LPI). Thirty-two cases had a BCL2 gene rearrangement, and one case had an extra copy of the BCL2 gene. This latter case had strong (4+) BCL2 staining by immunohistochemistry in >75% of the neoplastic cells and PI >30%, and was included in the BCL2-R/HPI group. Twenty-five cases had 2 copies of the intact BCL2 gene; the lack of BCL2 rearrangement was confirmed on the donor blocks for the 13 Cohort 2 cases derived from the TMA. The clinical and outcome data of the 4 BCL2/PI groups are shown in Table 2 .
There was no difference in the proportion of patients in each group treated with chemotherapy versus radiotherapy or observation only. While 0/13 patients in the BCL2-N/HPI group experienced relapse or disease progression, the majority of the patients in all other groups relapsed or progressed (p<0.0001) and had persistent FL at latest followup (p=0.0002). Table 3 . The BCL2-N/HPI cases occurred in younger patients (p=0.0005), with no predilection for gender or site ( Figure 6B ; Table 3 ). They were more likely to display follicles with prominent "starry-sky" appearance (p=0.001), be histologic grade 3 (p=0.004), and lack diffuse areas (p=0.04). Among all 28 Cohort 2 Stage I FL cases, BCL2-N/HPI status was associated with lack of relapse/progression (p<0.0001) or persistent disease at latest followup (p=0.02) ( Table 3) . stage I patients, grade 3 histology (p=0.008) and prominent "starry-sky" follicles (p=0.06), but not follicle size or presence/absence of diffuse areas, were associated with longer freedom from progression or relapse (log rank test, data not shown). Neither patient age nor gender was associated with freedom from progression or relapse (data not shown).
Evaluation of BCL2-N/HPI cases in both pediatric and adult FL (Cohorts 1 and 2)
Based on our finding that the BCL2-N/HPI status was associated with favorable outcome in FL in both Cohorts 1 and 2 and was often also associated with histologic features traditionally attributed to "pediatric FL" (expansile follicles, "starry-sky" appearance, and grade 3 histology), we compared the clinical and pathologic features and outcome of all BCL2-N/HPI FL cases (combined Cohorts 1 and 2) in patients aged <18 years versus those in patients >=18 years of age (Table 4) 
Discussion
We have analyzed clonal follicular proliferations in children and young adults, in an attempt to better define pediatric follicular lymphoma (PFL). We found that cases that lacked a BCL2 gene abnormality by FISH (BCL2-N) and had a high (>30%) proliferation index (HPI) uniformly had stage I disease and did not progress or relapse, even when treated with excision alone. The majority of these BCL2-N/HPI cases had histologic features consistent with pediatric follicular lymphoma, such as large, expansile follicles, as previously described in the literature 2-4,10,11 . However, this group also included some cases with small, round follicles composed predominantly of small centrocytes, morphologically resembling conventional grade 1-2 FL rather than PFL. In contrast to 
BCL2-N/HPI status was an important determinant of this indolent behavior in adults.
It is possible that BCL2-N/HPI FL cases may be related to a broad group of indolent extranodal clonal follicular lymphomas that lack BCL2 gene abnormalities, such as primary cutaneous follicle center lymphoma (PCFCL) 12 . PCFCL shares some features with pediatric-type FL, including follicles often composed of large centrocytes and variable proportion of centroblasts, negative (sometimes weak) expression of BCL2 by neoplastic cells, and lack of BCL2 gene rearrangement. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . This group of indolent clonal follicular proliferations may also include primary follicular lymphoma of the testis (in both adults and children), which also are characteristically localized and have CD10+, BCL6+, BCL2-neoplastic cells, but lack BCL2 gene rearrangements and do not generally progress or recur after orchiectomy [23] [24] [25] . More recently, PFL-like proliferations of the ovary with low stage, grade 3A histology, and lacking BCL2 rearrangement have been described that have more favorable outcome as compared with conventional FL of the ovary with respect to progression and recurrence. 26 These indolent types of FL are characterized by architectural effacement, which distinguishes them from previously described cases of follicular hyperplasia with clonal B cells 27 .
Proliferation index has been shown to have prognostic significance in FL and tends correlate with the number of large cells and histologic grade 28 . In one series, cases of FL with low grade and discordantly high proliferation index (LGHPI) were found to behave more aggressively than their non-HPI counterparts, and had inferior disease specific survival more akin to grade 3 FL 8 . In contrast to the LGHPI cases in our study, BCL2 protein expression was present in 20/24 of the
LGHPI cases in that study, and BCL2 gene rearrangement status was not assessed. These data suggest that HPI may be associated with more aggressive behavior in the setting of FL with BCL2 gene abnormalities, but not in the setting of BCL2 non-rearranged clonal follicular proliferations.
This idea is supported by a recent study demonstrating significant genetic alteration and gene expression profile differences between t(14;18) positive and t(14;18) negative FL cases, the latter of which mostly were of low stage and had an elevated PI 29 . Although overall survival did not differ between FL with and without t(14;18) in that series, freedom from progression or relapse were not translocation or strong IRF4 expression, indicating that these IG-IRF4 cases appear to be biologically distinct from the pediatric-type FL described in our series and may represent a spectrum of DLBCL in childhood, rather than a FL subtype. Oschlies et. al also described a series of high grade FL and DLBCL cases in children that had long event-free survival after treatment with chemotherapy. The majority of these patients presented with advanced stage and tumors were mostly negative for BCL6, BCL2 and MYC translocations; a small subset demonstrated IGH translocations for which the partner was not identified 40 . These cases may also fall within the spectrum of DLBCL in children, and are unlike the cases of pediatric-type FL described in this report, which were uniformly localized and show excellent event-free survival even in the absence of treatment with chemotherapy or radiotherapy.
In summary, using FISH for BCL2 rearrangement and the Ki67 proliferation index, we have shown that the combination of a normal BCL2 gene and a high proliferation index (BCL2-N/HPI phenotype) identifies a type of nodal FL in both children and adults that is localized and displays highly indolent clinical behavior. Although most cases have morphologic features similar to those previously described in PFL, some are morphologically indistinguishable from conventional lowgrade adult follicular lymphoma. These proliferations occur most frequently in the head and neck and have a male predominance. Importantly, while these cases occur predominantly in young patients, they can also occur in adult patients and appear to have the same indolent behavior. We propose the term 'pediatric-type' follicular lymphoma to encompass cases of Stage I nodal FL that both lack BCL2 gene abnormalities by FISH and have high PI by Ki67 immunohistochemistry. The localized nature and benign clinical course of these lesions raises the question of whether these are Further study is required to determine if pediatric-type FL occurring in adults may be effectively managed by excision alone, similar to pediatric-type FL occurring in children.
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